Welcome to the seventh volume of *Hepatic Oncology*, I would like to take this opportunity to wish all our readers a happy new year!

In this foreword I will be reflecting on 2019, discussing some of the journals highlights, as well as evaluating some of our fantastic content.

Readership & author demographics {#S0001}
================================

*Hepatic Oncology* has continued its wide reach in 2019, with our content accessed by readers all over the globe. The majority of our readers came from Asia (42%), with North America following (33%) and Europe in third place (18%; [Figure 1](#F1){ref-type="fig"}).We are delighted to report that in 2019 *Hepatic Oncology* experienced a 118% increase in readers from 2018, we are hoping we can replicate this success in 2020.

![Readership demographics by continent for *Hepatic Oncology* in 2019.](hep-07-14-g1){#F1}

Most of our contributing authors this year came from Europe (56%), with the remaining contributors coming equally from North America and Asia (both 22%; [Figure 2](#F2){ref-type="fig"}). We are keen to collaborate with authors all around the world.

![Author demographics by continent for *Hepatic Oncology* in 2019.](hep-07-14-g2){#F2}

Content highlights of 2019 {#S0002}
==========================

Our most read article of the year was a review from Raoul *et al.* entitled '*Current options and future possibilities for the systemic treatment of hepatocellular carcinoma*' \[[@B1]\]. This review examines the current first- and second-line systemic therapies available for the treatment of hepatocellular carcinoma, while also proposing a potential treatment algorithm.

The second article I would like to highlight is an editorial from Sean P Martin & Xin Wei Wang entitled '*The evolving landscape of precision medicine in primary liver cancer*' \[[@B2]\]. It discusses current applications and potential inadequacies of precision medicine for the treatment of primary liver cancer, as well as examining whether precision medicine can result in improved outcomes.

Social media {#S0003}
============

*Hepatic Oncology* is active on social media and encourages our readers to follow us on twitter (\@fsghep) in order to keep up to date with our latest content. We discuss the latest news and research surrounding liver cancer as well as our newly published articles. This platform allows us to engage with our readers and experts in the field alike.

Conclusion {#S0004}
==========

Our readers are pivotal to the success of *Hepatic Oncology* and we are always seeking feedback to ensure the journal is the best it can be. Please do not hesitate to get in contact with any suggestions that you may have. We welcome a wide range of unsolicited article types, so please contact us if you are interested in submitting to the journal.

I would finally like to thank our authors, reviewers and editorial board for their hard work and continued support. I hope to build on the success of 2019 and am excited to see the continued development of the journal.
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